X4 Pharmaceuticals (XFOR) Cash from Financing Activities (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Cash from Financing Activities for 10 consecutive years, with $75000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Financing Activities fell 98.67% year-over-year to $75000.0; the trailing twelve-month figure through Jun 2026 stood at $233.1 million (up 3942.21% YoY), and the FY2025 full-year result was $238.6 million, up 1075.85% from the prior year.
• Cash from Financing Activities advanced to $75000.0 in Q2 2026 per XFOR's latest filing, from $2000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $146.1 million in Q4 2025 and bottomed at -$2.1 million in Q1 2023.
• Historically, Cash from Financing Activities has averaged $31.0 million across 5 years, with a median of $5.6 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities slumped 142.86% in 2023, then surged 108116.3% in 2025.
• Over 5 years, Cash from Financing Activities stood at $60.6 million in 2022, then slumped by 99.84% to $97000.0 in 2023, then jumped by 39.18% to $135000.0 in 2024, then soared by 108116.3% to $146.1 million in 2025, then plunged by 99.95% to $75000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $75000.0, $2000.0, and $146.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.